In Situ

When a pathologist uses the phrase 'in situ,' they are describing cells that look abnormal under the microscope — sometimes clearly cancerous in appearance — but that remain confined to their original tissue layer. They have not broken through the basement membrane, the thin boundary that separates a tissue layer from the deeper structures around it. In the breast, this most commonly refers to the ducts or lobules, the milk-producing structures of the breast.

Ductal carcinoma in situ (DCIS) means abnormal cells are present inside the milk ducts but have not spread into the surrounding breast tissue. LCIS, or lobular carcinoma in situ, refers to abnormal cells in the lobules. DCIS is considered a pre-cancer or very early cancer and is typically treated with surgery, often followed by radiation. LCIS, by contrast, is generally regarded more as a risk indicator than a true cancer — meaning it signals elevated risk for future invasive breast cancer in either breast rather than being a cancer itself.

The word 'carcinoma' in these diagnoses can understandably feel alarming, but the 'in situ' distinction is clinically meaningful: because these cells have not invaded, they cannot spread to lymph nodes or other organs at this stage. Treatment is focused on preventing the possibility of future progression to invasive cancer, and outcomes for in-situ diagnoses are generally excellent.

Receiving a DCIS or LCIS diagnosis can be disorienting — the words 'carcinoma' or 'cancer cells' are frightening, but the 'in situ' qualifier is genuinely good news. It means any abnormal cells were caught at a stage when they have not yet invaded, giving you and your medical team significant flexibility in how to respond.

Understanding the difference between in-situ and invasive disease helps you ask better questions about your specific situation: How large is the area involved? What grade are the cells? What treatment options are on the table, and what are the trade-offs? For DCIS, active surveillance is an emerging area of research for low-risk cases, and your oncologist can help you understand whether you are a candidate. For LCIS, the focus shifts to ongoing monitoring and, in some cases, risk-reduction strategies. Either way, catching abnormal cells before invasion is precisely what early detection is designed to achieve.